Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immunic (GB:0LQI)
LSE:0LQI
Holding GB:0LQI?
Track your performance easily
0LQI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.48 - $7.48
Previous Close$7.48
Volume0.00
Average Volume (3M)N/A
Market Cap
$140.52M
Enterprise Value$55.66M
Total Cash (Recent Filing)$79.70M
Total Debt (Recent Filing)$241.00K
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Nov 07, 2024EPS Estimate
-$0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding90,079,016
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard Deviation1.17
R-Squared0.03
Alpha0.29
Financial Highlights & Ratios
Price to Book (P/B)1.46
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.60
Forecast
1Y Price Target
$17.00Price Target Upside127.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Immunic News
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyVido demonstrated significant efficacy in clinical trials, including a 76% reduction in cumulative unique active lesions and a 78% reduction in gadolinium-enhancing lesions in patients with relapsing-remitting MS.
Competitive PositioningAnalyst's recommendation reiterates a Buy rating on Immunic, Inc. after conference updates, pointing to materially improved competitive positioning of vidofludimus calcium among its peer late-stage MS therapeutics.
Safety ProfileVido's improved safety profile is expected to make it superior to current treatments like teriflunomide, which has a black box warning, and BTK inhibitors, which have faced clinical holds.
Bears Say
Clinical TrialsThe Phase 3 ENSURE study in RMS is seen as a lower risk, smaller reward opportunity.
Drug Market PositionGiven past tolerability troubles plaguing BTKi drug class, vido could remain as the last oral option standing.
Drug SafetyOutstanding questions on tolebrutinib's liver toxicity remain, with few details provided in the presentation.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.76% Insiders
5.35% Mutual Funds
51.24% Other Institutional Investors
41.65% Public Companies and
Individual Investors
0LQI FAQ
What was Immunic’s price range in the past 12 months?
Immunic lowest share price was $7.48 and its highest was $7.48 in the past 12 months.
What is Immunic’s market cap?
Currently, no data Available
When is Immunic’s upcoming earnings report date?
Immunic’s upcoming earnings report date is Nov 07, 2024 which is in 42 days.
How were Immunic’s earnings last quarter?
Immunic released its earnings results on Aug 08, 2024. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.232 by $0.022.
Is Immunic overvalued?
According to Wall Street analysts Immunic’s price is currently Undervalued.
Does Immunic pay dividends?
Immunic does not currently pay dividends.
What is Immunic’s EPS estimate?
Immunic’s EPS estimate is -$0.22.
How many shares outstanding does Immunic have?
Immunic has 90,079,020 shares outstanding.
What happened to Immunic’s price movement after its last earnings report?
Immunic reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.232. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Immunic?
Among the largest hedge funds holding Immunic’s share is Omega Fund Management, LLC. It holds Immunic’s shares valued at 2M.
---
Immunic Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.00 (127.27% Upside)
$17.00 (127.27% Upside)
Blogger Sentiment
Bullish
GB:0LQI Sentiment 100%
Sector Average 71%
Sector Average 71%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.29%
12-Months-Change
Fundamentals
Return on Equity
-143.47%
Trailing 12-Months
Asset Growth
-2.53%
Trailing 12-Months
Company Description
Immunic
Immunic, Inc. engages in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.
---
0LQI Company Deck
---
0LQI Earnings Call
Q2 2024
0:00 / 0:00
---
0LQI Stock 12 Month Forecast
Average Price Target
$17.00
▲(127.27% Upside)
Technical Analysis
Immunic
―
Adaptimmune Therapeutics
―
Atara Biotherapeutics
―
Corbus Pharmaceuticals
―
Kiniksa Pharmaceuticals
―
Best Analysts Covering 0LQI
1 Year
1 Year Success Rate
3/9 ratings generated profit
1 Year Average Return
-1.36%
reiterated a buy rating 7 months ago
Copying Andreas Argyrides's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -1.36% per trade.
---